So just looking into this director appointment a bit more. This is one serious appointment.
Wisenberg is Bridgewest Groups Operating Partner and the Group’s representative in Australasia.
Bridgewest Group is a privately held global investment firm with over $3B in private capital with reputation for scaling transformational businesses and expertise in Life Sciences, Software, Semiconductor and Artificial Intelligence/Deep Tech.
Wisenberg led the acquisition of Bridgewest Groups first biologics manufacturing facility and operation from Pfizer in Adelaide. And present role is Executive Chairman of that facility BioCina.
Biocina and Novacina formed a strategic alliance in Feb this year. We have a an instrument with Novacina.
https://biocina.com/press-releases/biocina-and-novacina-forge-strategic-alliance-to-offer-biologics-developers-integrated-drug-substance-and-drug-product-solutionsbiocina-and-novacina-forge-strategic-alliance-to-offer-biologics-develop/
So on top of the Wispinghoffs, who own ones of Europe's largest private labs, and took a recent big strategic stake in this company......we now have this appointment
The market in my opinion is not pricing the potential of this business whatsoever considering such big fundamental changes have taken place
Add to My Watchlist
What is My Watchlist?
